Medifron DBT Co., Ltd. (065650) Dips -0.33% on Feb 14

February 14, 2018 - By Darrin Black

Shares of Medifron DBT Co., Ltd. (KOSDAQ:065650) last traded at 6070, representing a move of -0.33%, or -20 per share, on volume of 152,504 shares. After opening the trading day at 6110, shares of Medifron DBT Co., Ltd. traded in a close range. Medifron DBT Co., Ltd. currently has a total float of 25.63M shares and on average sees 1.34 million shares exchange hands each day. The stock now has a 52-week low of 3478.63 and high of 7680.

How KOSPI Transforms South Korea Into A Global Leader

One of the leading economies backing the immense growth of the Asian economy is that of South Korea. The country has long been proven itself as a valuable asset in driving growth and maximizing potentials in the long run. It is not easy for companies to get there, but as Medifron DBT Co., Ltd. shows it is possible. Its rich and healthy equity market is only one of the many proofs of South Korea’s capabilities.

About the KOSPI

The Korea Composite Stock Price Index (KOSPI) is the benchmark, market-capitalization-weighted index in South Korea. Medifron DBT Co., Ltd. is inside KOSPI register. First published in 1983, it has replaced the Korea Composite Stock Price Index (KCSPI), which was like the Dow Jones Industrial Average (DJIA) of the US equity market.

The KOSPI has a base value of 100 points— the base date being January 4, 1980. It measures companies listed on the Stock Market Division of the Korea Exchange (KRX) based on market capitalization. The KRX is one of the biggest stock exchanges in Asia, boasting with a total market capitalization of $1.20 trillion as of January 2015.

With hundreds of components, the KOSPI had to be divided into several, smaller sub-indices to provide a clearer real-time representation of the South Korean equity market. These sub-indices include the KOSPI 200, which tracks the top 200 companies on the Stock Market Division of the KRX; the KOSPI 100, which tracks the top 100 companies; and the KOSPI 50, which tracks the top 50 companies. Because of its broad nature, the KOSPI 200, which represents about 70% of the total market capitalization on the Stock Market Division of the KRX, shares the same movement with the KOSPI at most times.

Perfect liquidity made it easier for Medifron DBT Co., Ltd. to get there. A stock needs to be included in the KOSPI 200 before becoming eligible for inclusion in the KOSPI 100. Similarly, it needs to be included in the KOSPI 100 before becoming eligible for inclusion in the KOSPI 50.

KOSPI Performance

The KOSPI had posted its biggest one-day gain of 8.50% or 23.81 points on June 17, 1998. This is largely attributed to the recovery of the Asian economy following the massive financial crisis that had begun in Thailand.

Meanwhile, the KOSPI had posted its biggest one-day decline of 12.02% or 64.97 points on September 12, 2001. This is widely attributed to the bombing of the twin towers in the US on September 11, 2001, a tragedy that had affected the global economy by causing widespread panic among investors.

The KOSPI holds an all-time low of 93.10 points, which was last seen in January 1981; and an all-time high of 2,228.98 points, which was last seen in May 2011. It had first hit the 2,000-point mark on July 24, 2007, a year before the 2008 Global Financial Crisis broke out.

In 2014, Asia had accounted for about 24% of global financial wealth. In five years time from then, the region is anticipated to represent 26% of global financial wealth. Investing in the healthy South Korean equity market is likely healthy for investors. By doing so, they can expect to reap gains from the Asian economy bloom. They can also check the benefits of Medifron DBT Co., Ltd..

More recent Medifron DBT Co., Ltd. (KOSDAQ:065650) news were published by: Businesswire.com which released: “Diabetic Peripheral Neuropathy – Pipeline Review, H1 2017 – Research and Markets” on March 14, 2017. Also Prnewswire.com published the news titled: “Diabetic Neuropathy Pipeline Therapeutics Assessment and Drug Profiles …” on June 02, 2017. Prnewswire.com‘s news article titled: “Global Pain Drug Development Pipeline Review Report 2017 Featuring 170+ …” with publication date: July 10, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts